Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
ER positive (ER+) and HER2 negative (HER2-) breast cancers are routinely treated based on estrogen dependence. CDK4/6 inhibitors in combination with endocrine therapy have significantly improved the progression-free survival of patients with ER+/HER2- metastatic breast cancer. Gene expression profil...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Language: | en |
| Published: |
IMPACT JOURNALS LLC
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10150/622114 http://arizona.openrepository.com/arizona/handle/10150/622114 |